Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Infrared Spectrometry Method Used for Triage of Brain Cancer Patients

By LabMedica International staff writers
Posted on 23 Oct 2019
A team of British researchers has adapted an advanced spectrophotometric method for use in brain cancer testing as a triage tool to speed up the diagnostic process.

Non-specific symptoms, as well as the lack of a cost-effective test to triage patients in primary care, has resulted in increased time-to-diagnosis and a poor prognosis for brain cancer patients. More...
A rapid, cost-effective, triage test could significantly improve this scenario.

Towards this end, investigators at the University of Strathclyde (Glasgow, United Kingdom), the spinoff biotechnology company ClinSpec Diagnostics Limited (Glasgow, United Kingdom), and colleagues at other institutions developed instrumentation based on testing blood samples by attenuated total reflection (ATR)-Fourier transform infrared (FTIR) spectroscopy to differentiate cancer and control patients.

Fourier-transform infrared spectroscopy (FTIR) is a technique used to obtain an infrared spectrum of absorption or emission of a solid, liquid, or gas. An FTIR spectrometer simultaneously collects high-spectral-resolution data over a wide spectral range. This confers a significant advantage over a dispersive spectrometer, which measures intensity over a narrow range of wavelengths at a time. The term Fourier-transform infrared spectroscopy originates from the fact that a Fourier transform (a mathematical process) is required to convert the raw data into the actual spectrum. Attenuated total reflection (ATR) is a sampling technique used in conjunction with infrared spectroscopy, which enables samples to be examined directly in the solid or liquid state without further preparation.

The investigators developed disposable sample slides that allowed the rapid preparation and analysis of multiple samples, enabling high-throughput ATR-FTIR spectroscopy optimized for clinical research. Based upon the design of a microscope slide, these optical sample slides contained four sample areas; one for background measurements and three for repeat measurements of a single patient. This device was developed for the triplicate measurement of patient samples with optimized spectral throughput and performance.

The investigators described the transition to this technology for the established application of ATR-FTIR spectroscopy of blood serum for the detection of brain cancer, and the subsequent impact on clinical diagnostics. In the current study, they analyzed samples from a prospective cohort of 104 patients and found that the blood test was able to differentiate cancer and control patients at a sensitivity and specificity of 93.2% and 92.8%, respectively.

Senior author Dr. Matthew J. Baker, reader in pure and applied chemistry at Strathclyde University and CSO at ClinSpec Diagnostics, said, "This is the first publication of data from our clinical feasibility study and it is the first demonstration that our blood test works in the clinic. Earlier detection of brain tumors in the diagnostic pathway brings the potential to significantly improve patient quality of life and survival, whilst also providing savings to the health services."

The clinical feasibility study was published in the October 8, 2019, online edition of the journal Nature Communications.

Related Links:
University of Strathclyde
ClinSpec Diagnostics Limited


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.